

MEDICAL POLICY



SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS	EFFECTIVE DATE: 01/20/00 REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18
POLICY NUMBER: 2.01.24 CATEGORY: Technology Assessment	PAGE: 1 OF: 6
<ul style="list-style-type: none">• <i>If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</i>• <i>If a commercial product, including an Essential Plan product, covers a specific service, medical policy criteria apply to the benefit.</i>• <i>If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</i>	

POLICY STATEMENT:

- I. Recombinant Platelet-Derived Growth Factors: Becaplermin gel, Regranex®
- A. Based upon our criteria and assessment of peer-reviewed literature, recombinant human platelet-derived growth factor (Becaplermin gel) for topical administration has been medically proven to be effective and therefore **medically appropriate** when used as an adjunct to standard wound management for *neuropathic diabetic ulcers* extending into the subcutaneous tissue. Appropriate candidates should meet **ALL** of the following criteria:
1. Adequate tissue oxygenation, as measured by:
 - a. a transcutaneous partial pressure of oxygen of 30 mm Hg or greater on the foot dorsum or at the margin of the ulcer, or
 - b. an ankle-brachial blood pressure index (ABI) greater than 0.70 or ankle systolic pressure greater than 70 mm Hg
 2. Full-thickness ulcer (ie, stage III or IV), extending through dermis into subcutaneous tissues
 3. Participation in a wound management program, which includes sharp debridement, pressure relief (ie, non-weight bearing), and infection control.
- B. Based upon our criteria and lack of peer-reviewed literature, Becaplermin gel has not been medically proven to be effective and is considered **investigational** for all of the following indications:
1. Ischemic diabetic ulcers
 2. Venous stasis ulcers
 3. Pressure ulcers
 4. Ulcers not extending through the dermis into the subcutaneous tissue
 5. Surgical wounds
 6. Ulcerated perineal hemangiomas of infancy
- II. Autologous Platelet-Derived Preparations: Basic Fibroblast Growth Factor (BFGF), Epidermal Growth Factor (EGF), Placental Angiogenic Growth Factors (PGF's), and Platelet-Rich Plasma (PRP)
- Based upon our criteria and lack of peer-reviewed literature, autologous platelet-derived preparations have not been medically proven to be effective and are considered **investigational** in the treatment of:
- A. Chronic non-healing wounds
 - B. Surgical wounds
 - C. All other conditions including, but not limited to: arthritis, Dupuytren's contracture, epicondylitis, plantar fasciitis, and tendinopathy.

This policy does not address fibrin sealants.

Refer to Corporate Medical Policy #7.01.35 regarding Bioengineered Tissue Products for Wound Treatment and Surgical Interventions.

Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.

<p>SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS</p> <p>POLICY NUMBER: 2.01.24</p> <p>CATEGORY: Technology Assessment</p>	<p>EFFECTIVE DATE: 01/20/00</p> <p>REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18</p> <p>PAGE: 2 OF: 7</p>
---	---

POLICY GUIDELINES:

- I. Patients are typically treated once daily for up to 20 weeks. Continuing Becaplermin treatment should be reconsidered if the ulcer is not reduced in size by 30% within 10 weeks of treatment or complete healing has not occurred in 20 weeks. When expected reduction in ulcer size occurs successfully, the treatment is continued until the ulcer is completely healed. The increase in rate of healing must be balanced with the potential for increased risk from cancer. Application of the gel may be performed by the patient in the home.
- II. When purchased at a pharmacy, coverage for Becaplermin gel is dependent upon the member’s prescription drug coverage.
- III. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

Growth Factors are polypeptides produced by cells during development and in response to injury. Owing to their effects on cell proliferation, growth factors have undergone extensive analyses to determine their usefulness as wound healing agents.

A recombinant human platelet-derived growth factor, Becaplermin gel/Regranex®, has biological activity similar to that of endogenous platelet-derived growth factor that includes promoting chemotactic recruitment and proliferation of cells involved in wound repair and enhancing of granulation tissue.

Examples of growth factors used in wound healing are:

- I. Basic Fibroblast Growth Factor (BFGF),
- II. Epidermal Growth Factor (EGF),
- III. Placental Angiogenic Growth Factors (PGF’s), and
- I. Platelet-Derived Growth Factor (PDGF).

Autologous platelet-derived growth factor is one of the polypeptides that control growth, differentiation, and activation of cell types essential for wound healing. The growth promoting activities of platelet-derived growth factor (PDGF) are thought to be deficient in chronic wounds. Autologous platelet-derived growth factor preparations have been proposed as an adjuvant therapy for wound healing and to enhance healing following various types of surgery (e.g., oral and maxillofacial surgery, dental implants, non-union fractures).

Platelet-rich plasma (PRP) preparations, which contain growth factors, have been proposed as a primary treatment of miscellaneous conditions, such as arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis and tendinopathy. The effectiveness of PDGF and PRP use, for these conditions, has not been demonstrated in the peer-reviewed literature.

RATIONALE:

Becaplermin (Regranex) gel has been approved by the FDA specifically for use in the treatment of chronic neuropathic diabetic ulcers of the lower extremities. Becaplermin gel, in conjunction with a good wound care program, has been found to improve health outcomes of patients with chronic neuropathic diabetic ulcers by producing complete wound healing and reducing the time to complete wound healing when compared to a good wound care program alone.

In 2008, the manufacturer of Regranex gel, Ortho-McNeil Pharmaceutical, added a black box warning to the labeling stating an increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of Regranex gel in a post-marketing retrospective cohort study, Regranex gel should only be used when the benefits can be expected to outweigh the risks, and Regranex gel should be used with caution in patients with known malignancy.

Available data are insufficient to permit positive conclusions regarding the use of Becaplermin gel for treatment of ulcers (e.g., ischemic diabetic ulcers, pressure ulcers, and venous ulcers), other than chronic neuropathic diabetic ulcers, or other non-healing wounds in the investigational setting.

Evidence is insufficient regarding the use of platelet-derived growth factors as a treatment of chronic non-healing wounds, surgical wounds, and other conditions, including but not limited to, arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis, or tendinopathy.

SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS POLICY NUMBER: 2.01.24 CATEGORY: Technology Assessment	EFFECTIVE DATE: 01/20/00 REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18 PAGE: 3 OF: 7
--	--

A 2015 statement by the American Academy of Orthopedic Surgeons states “Biologic therapies are becoming increasingly popular in orthopedics due to their potential to regenerate tissue and enhance bone healing. However, questions still remain about their efficacy and indications for use.”

Published studies provide mixed results regarding the use of PRP; with some showing benefit of the treatment while others show no or little benefit. Proof of the efficacy of PRP has not been demonstrated in clinical studies and further well-designed, randomized, controlled studies are needed before conclusion can be made.

The 2017 publication of the American Academy of Orthopedic Surgeons: Management of Osteoarthritis of the Hip Evidence-based Clinical Proactive Guideline they concluded that, “No high quality randomized controlled trials were available comparing the performance of IA injection of stem cells or prolotherapy to placebo. Three studies (Battaglia et al , Dallari et al) compared IA injections of platelet-rich plasma (PRP) versus HA or a combination of PRP and HA. However, *no high quality studies comparing PRP with placebo were available for inclusion.*”

CODES: Number Description

Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT: 0232T (E/I) Injection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
Copyright © 2018 American Medical Association, Chicago, IL

HCPCS: G0460 (E/I) Autologous platelet rich plasma for chronic wounds/ulcers including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment

P9020 (E/I) Platelet rich plasma, each unit

S0157 Becaplermin gel 0.01%, 0.5 gm

S9055 Procuren or other growth factor preparation to promote wound healing

NDC: 50484-0810-15 Becaplermin

ICD10: Medically Appropriate codes for when criteria is met under Policy Statement IA:

E08.621 Diabetes mellitus due to underlying condition with foot ulcer

E08.622 Diabetes mellitus due to underlying condition with other skin ulcer

E09.621 Drug or chemical induced diabetes mellitus with foot ulcer

E09.622 Drug or chemical induced diabetes mellitus with other skin ulcer

E10.621 Type 1 diabetes mellitus with foot ulcer

E10.622 Type 1 diabetes mellitus with other skin ulcer

E11.621 Type 2 diabetes mellitus with foot ulcer

E11.622 Type 2 diabetes mellitus with other skin ulcer

E13.621 Other specified diabetes mellitus with foot ulcer

SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS POLICY NUMBER: 2.01.24 CATEGORY: Technology Assessment	EFFECTIVE DATE: 01/20/00 REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18 PAGE: 4 OF: 7
--	--

E13.622 Other specified diabetes mellitus with other skin ulcer

ICD10: Investigational codes (See Policy Statement IB):

- I70.231-I70.249 Atherosclerosis of native arteries of leg with ulceration (code range)
- I70.331-I70.349 Atherosclerosis of unspecified type of bypass graft(s) of leg with ulceration (code range)
- I70.431-I70.449 Atherosclerosis of autologous vein bypass graft(s) of the leg with ulceration (code range)
- I70.531-I70.549 Atherosclerosis of nonautologous biological bypass graft(s) of the leg with ulceration (code range)
- I70.631-I70.649 Atherosclerosis of nonbiological bypass graft(s) of the leg with ulceration (code range)
- I70.731-I70.749 Atherosclerosis of other type of bypass graft(s) of the leg with ulceration (code range)
- L97.101-L97.929 Non-pressure chronic ulcer of lower extremity (code range)
- L89.30-L89.95 Pressure ulcers (code range)

REFERENCES:

*Agency for Healthcare Research and Quality. Pressure ulcer treatment strategies: comparative effectiveness. AHRQ Pub. No. 13-EHC003-1-EF. 2013 May [https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/pressure-ulcer-treatment_executive.pdf] Accessed 1/22/18.

Aggarwal AK, et al. Platelet-rich plasma prevents blood loss and pain and enhances early functional outcome after total knee arthroplasty: a prospective randomized controlled study. Int Orthop 2014 Feb;38(2):387-95.

Ahmad Z, et al. The effect of platelet-rich plasma on clinical outcomes in lateral epicondylitis. Arthroscopy 2013 Nov;29(11):1851-62.

Alsousou J, et al. The role of platelet-rich plasma in tissue regeneration. Platelets 2013;24(3):173-82.

*American Academy of Orthopedic Surgeons. AAOS Now. Clinical use of platelet-rich plasma in orthopedics. 2007 Sep [http://www.aaos.org/news/bulletin/sep07/research2.asp] Accessed 1/22/18.

*American Academy of Orthopedic Surgeons: Management of Osteoarthritis of the Hip Evidence-based Clinical Proactive Guideline 3.13.17 [https://www.aaos.org/uploadedFiles/PreProduction/Quality/Guidelines_and_Reviews/OA%20Hip%20CPG_11.1.17.pdf] accessed 1/23/18.

Andia I and Maffulli N. Platelet-rich plasma for muscle injury and tendinopathy. Sports Med Arthrosc 2013 Dec;21(4):191-8.

Baksh N, et al. Platelet-rich plasma in tendon models: a systematic review of basic science literature. Arthroscopy 2013 Mar;29(3):596-607.

*Battaglia,M.; Guaraldi,F.; Vannini,F.; Rossi,G.; Timoncini,A.; Buda,R.; Giannini,S. Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. 2013/12: 12

*BlueCross BlueShield Association. Technology Evaluation Center. Becaplermin for wound healing. 1999 Jun;14(5).

BlueCross BlueShield Association. Orthopedic applications of platelet-rich plasma. Medical Policy Reference Manual Policy #2.01.98. 2017 Apr 13.

<p>SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS</p> <p>POLICY NUMBER: 2.01.24</p> <p>CATEGORY: Technology Assessment</p>	<p>EFFECTIVE DATE: 01/20/00</p> <p>REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18</p> <p>PAGE: 5 OF: 7</p>
---	---

BlueCross BlueShield Association. Recombinant and autologous platelet-derived growth factors as a treatment of wound healing and other non-orthopedic conditions. Medical Policy Reference Manual Policy #2.01.16. 2015 May 21.

Cardenosa EM, et al. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. J Tissue Viability. Nov 29 2016.

Chang KV, et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. Arch Phys Med Rehabil 2014 Mar;95(3):562-75.

*Dallari,D.; Stagni,C.; Rani,N.; Sabbioni,G.; Pelotti,P.; Torricelli,P.; Tschon,M.; Giavaresi,G. Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study. Am J Sports Med; 2016/3: 3

Dold AP, et al. Platelet-rich plasma in the management of articular cartilage pathology: a systematic review. Clin J Sport Med 2014 Jan;24(1):31-43.

El-Anwar MW, et al. Use of autologous platelet-rich plasma in complete cleft palate repair. Laryngoscope. Jul 2016;126(7):1524-1528.

Franceschi F, et al. Platelet-rich plasma injections for chronic plantar fasciopathy: a systematic review. Br Med Bull 2014 Dec;112(1):83-95.

Gallagher B, et al. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med 2015 Mar;43(3):734-44.

*Gosens T, et al. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med 2011 Jun;39(6):1200-8.

Gross CE, et al. Injectable treatments for noninsertional Achilles tendinosis: a systematic review. Foot Ankle Int 2013 May;34(5):619-28.

Khoshbin A, et al. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis. Arthroscopy 2013 Dec;29(12):2037-48.

Krogh TP, et al. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med 2013 Mar;41(3):625-35.

Krogh TP, et al. Comparative effectiveness of injection therapies in lateral epicondylitis: a systematic review and network meta-analysis of randomized controlled trials. Am J Sports Med 2013 Jun;41(6):1435-46.

*Lawlor DK, et al. The role of platelet-rich plasma in inguinal wound healing in vascular surgery patients. Vasc Endovascular Surg 2011 Apr;45(3):241-5.

Marck RE, et al. The application of platelet-rich plasma in the treatment of deep dermal burns: A randomized, double-blind, intra-patient controlled study. Wound Repair Regen. Jul 2016;24(4):712-720.

Martí-Carvajal AJ, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2015 Oct;10:CD008548.

Martinez-Zapata MJ, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev 2016 May 25;10:CD006899.

Mishra AK, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med 2014 Feb;42(2):463-71.

Moraes VY, et al. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev 2014 Apr 29;4:CD010071.

<p>SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS</p> <p>POLICY NUMBER: 2.01.24</p> <p>CATEGORY: Technology Assessment</p>	<p>EFFECTIVE DATE: 01/20/00</p> <p>REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18</p> <p>PAGE: 6 OF: 7</p>
---	---

Nourissat G, et al; French Arthroscopic Society (SFA). Current concept for the use of PRP in arthroscopic surgery. Orthop Traumatol Surg Res 2013 Dec;99(8 Suppl):S407-10.

Patel S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013 Feb;41(2):356-64.

Qaseem A, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Mar 03 2015;162(5):370-379.

Roffi A, et al. Does PRP enhance bone integration with grafts, graft substitutes, or implants? A systematic review. BMC Musculoskelet Disord 2013 Nov 21;14:330.

Ruiz-Moneo P, et al. Plasma rich in growth factors in arthroscopic rotator cuff repair: a randomized, double-blind, controlled clinical trial. Arthroscopy 2013 Jan;29(1):2-9.

*Smith ME, et al. Pressure ulcer treatment strategies: a systematic comparative effectiveness review. Ann Intern Med 2013 Jul 2;159(1):39-50.

Tietze DC, et al. The effects of platelet-rich plasma in the treatment of large-joint osteoarthritis: a systematic review. Phys Sportsmed 2014 May;42(2):27-37.

*U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Drug label: Regranex® Gel 0.01% (becaplermin). 2008 May. [http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM142821.pdf]. Accessed 1/23/18.

*U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Update of safety review: follow-up to the March 27, 2008, communication about the ongoing safety review of Regranex (becaplermin). Archived. 2008 Jun 6, page last updated 2013 Aug 15 https://wayback.archive-it.org/7993/20170406044646/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm072148.htm] Accessed 1/23/18.

U.S. Food and Drug Administration. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment. 2006 June; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071324.pdf. Accessed 1/23/18.

Vannini F, et al. Platelet-rich plasma for foot and ankle pathologies: a systematic review. Foot Ankle Surg 2014 Mar;20(1):2-9.

Warth RJ, et al. Clinical and structural outcomes after arthroscopic repair of full-thickness rotator cuff tears with and without platelet-rich product supplementation: a meta-analysis and meta-regression. Arthroscopy 2015 Feb;31(2):306-20.

Weber SC, et al. Platelet-rich fibrin matrix in the management of arthroscopic repair of the rotator cuff: a prospective, randomized, double-blinded study. Am J Sports Med 2013 Feb;41(2):263-70.

Zhao JG, et al. Platelet-rich plasma in arthroscopic rotator cuff repair: a meta-analysis of randomized controlled trials. Arthroscopy 2015 Jan;31(1):125-35.

KEY WORDS:

Becaplermin, Growth factors, Regranex, Platelet derived growth factor, PDGF, Platelet-rich plasma.

<p>SUBJECT: GROWTH FACTORS FOR WOUND HEALING AND OTHER CONDITIONS</p> <p>POLICY NUMBER: 2.01.24</p> <p>CATEGORY: Technology Assessment</p>	<p>EFFECTIVE DATE: 01/20/00</p> <p>REVISED DATE: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18</p> <p>PAGE: 7 OF: 7</p>
---	---

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD) for Blood-Derived Products for Chronic Non-Healing Wounds. Please refer to the following websites for Medicare Members:

<http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=217&ncdver=5&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Entire+State&KeyWord=blood+derived+products&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAABAAAAAAAA%3d%3d&>

-